Mirvaso Approval History
- FDA approved: Yes (First approved August 23rd, 2013)
- Brand name: Mirvaso
- Generic name: brimonidine
- Dosage form: Topical Gel
- Company: Galderma Laboratories, L.P.
- Treatment for: Rosacea
Mirvaso (brimonidine) topical gel is an alpha adrenergic agonist indicated for the topical treatment of facial erythema of rosacea.
Development History and FDA Approval Process for Mirvaso
|Aug 26, 2013||Galderma Receives FDA Approval of Mirvaso for the Topical Treatment of Facial Erythema of Rosacea|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.